Benutzer: Gast  Login
Titel:

NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

Dokumenttyp:
Article; Journal Article
Autor(en):
Pfister, Dominik; Núñez, Nicolás Gonzalo; Pinyol, Roser; Govaere, Olivier; Pinter, Matthias; Szydlowska, Marta; Gupta, Revant; Qiu, Mengjie; Deczkowska, Aleksandra; Weiner, Assaf; Müller, Florian; Sinha, Ankit; Friebel, Ekaterina; Engleitner, Thomas; Lenggenhager, Daniela; Moncsek, Anja; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; Leone, Valentina; Dudek, Michael; Yousuf, Suhail; Inverso, Donato; Singh, Indrabahadur; Teijeiro, Ana; Castet, Florian; Montironi, Carla; Haber, Phi...     »
Abstract:
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1-5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at prog...     »
Zeitschriftentitel:
Nature
Jahr:
2021
Band / Volume:
592
Heft / Issue:
7854
Seitenangaben Beitrag:
450-456
Volltext / DOI:
doi:10.1038/s41586-021-03362-0
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/33762733
Print-ISSN:
0028-0836
TUM Einrichtung:
1039; II. Medizinische Klinik und Poliklinik (Gastroenterologie); Professur für Translationale gastroenterologische Onkologie (Prof. Rad); Roman Herzog Comprehensive Cancer Center
 BibTeX